Comment on CMS-2026-1256-0002
Schizophrenia Policy Action Network (SPAN)SupportAdvocacy
Summary: The Schizophrenia Policy Action Network (SPAN) supports the New Technology Add-On Payment (NTAP) application for COBENFY. They argue that the drug provides substantial clinical improvement for a significant subpopulation of Medicare beneficiaries who are unresponsive to or cannot tolerate existing dopamine-targeting therapies, citing new peer-reviewed evidence on the high societal costs of inadequate treatment.
The Schizophrenia Policy Action Network (SPAN) submits the attached comment in response to the FY 2027 IPPS/LTCH PPS proposed rule, regarding the New Technology Add-On Payment (NTAP) application for COBENFY (xanomeline-trospium).